The expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are molecular markers that classify breast cancer subtype, determine the prognosis, and carry significant implications for treatment across all age groups. This evidence concerns the gene ERBB2 and breast carcinoma.